The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Aerovate Therapeutics, Inc. | Common Stock | 008064107 | 41,237 | 2,638,297 | SH | SOLE | 2,638,297 | 0 | 0 | ||
Akero Therapeutics, Inc. | Common Stock | 00973Y108 | 21,095 | 2,232,251 | SH | SOLE | 2,232,251 | 0 | 0 | ||
AvroBio, Inc. | Common Stock | 05455M100 | 4,159 | 4,520,863 | SH | SOLE | 4,520,863 | 0 | 0 | ||
Day One Biopharmaceuticals, Inc. | Common Stock | 23954D109 | 160,533 | 8,968,305 | SH | SOLE | 8,968,305 | 0 | 0 | ||
Dyne Therapeutics, Inc. | Common Stock | 26818M108 | 61,383 | 8,934,902 | SH | SOLE | 8,934,902 | 0 | 0 | ||
F-star Therapeutics, Inc. | Common Stock | 30315R107 | 3,753 | 599,524 | SH | SOLE | 599,524 | 0 | 0 | ||
Gemini Therapeutics, Inc. | Common Stock | 36870G105 | 8,880 | 5,254,365 | SH | SOLE | 5,254,365 | 0 | 0 | ||
Generation Bio, Co. | Common Stock | 37148K100 | 54,309 | 8,278,876 | SH | SOLE | 8,278,876 | 0 | 0 | ||
Ikena Oncology, Inc. | Common Stock | 45175G108 | 22,231 | 5,018,178 | SH | SOLE | 5,018,178 | 0 | 0 | ||
Kymera Therapeutics, Inc. | Common Stock | 501575104 | 135,382 | 6,875,698 | SH | SOLE | 6,875,698 | 0 | 0 | ||
Magenta Therapeutics, Inc. | Common Stock | 55910K108 | 4,172 | 3,476,536 | SH | SOLE | 3,476,536 | 0 | 0 | ||
Replimune Group, Inc. | Common Stock | 76029N106 | 56,104 | 3,209,627 | SH | SOLE | 3,209,627 | 0 | 0 | ||
Spero Therapeutics, Inc. | Common Stock | 84833T103 | 764 | 1,031,160 | SH | SOLE | 1,031,160 | 0 | 0 | ||
Vigil Neuroscience, Inc. | Common Stock | 92673K108 | 15,059 | 5,836,874 | SH | SOLE | 5,836,874 | 0 | 0 | ||
Viridian Therapeutics, Inc. | Common Stock | 92790C104 | 1,042 | 90,072 | SH | SOLE | 90,072 | 0 | 0 | ||
Xilio Therapeutics, Inc. | Common Stock | 98422T100 | 8,057 | 2,759,344 | SH | SOLE | 2,759,344 | 0 | 0 |